Sentinus LLC’s Northwest Biotherapeutics NWBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-12,925
Closed -$3.55K – 210
2024
Q4
$3.55K Buy
+12,925
New +$3.55K ﹤0.01% 182
2024
Q3
– Sell
-12,925
Closed -$5.52K – 197
2024
Q2
$5.52K Buy
+12,925
New +$5.52K ﹤0.01% 182
2023
Q2
$1.4M Buy
2,469,440
+279,000
+13% +$158K 0.44% 42
2023
Q1
$1.37M Buy
2,190,440
+395,650
+22% +$247K 0.46% 46
2022
Q4
$1.45M Buy
1,794,790
+600,375
+50% +$484K 0.85% 30
2022
Q3
$1.02M Buy
+1,194,415
New +$1.02M 0.64% 36

Other funds holding NWBO

Sentinus LLC's NWBO Position: Q1 2025 in Review

Sentinus LLC sold out of Northwest Biotherapeutics (NWBO) in Q1 2025, closing a stake of 12,925 shares — an estimated $3.55K sold.

Sentinus LLC first reported a position in NWBO in Q3 2022 and held it in 6 quarters. The position peaked at $1.45M in Q4 2022. 8 funds tracked by Wall St. Rank hold NWBO as of Q1 2025.

  • Sentinus LLC reported no remaining Northwest Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Sentinus LLC sold 12,925 Northwest Biotherapeutics shares in Q1 2025, an estimated $3.55K.
  • Sentinus LLC first reported a position in Northwest Biotherapeutics in Q3 2022 and held it in 6 quarters.
  • Sentinus LLC's Northwest Biotherapeutics position peaked at $1.45M in Q4 2022.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics as of Q1 2025.

Based on Sentinus LLC's 13F filing for Q1 2025, filed 15 May 2025.